Afexa Life Sciences Inc.
TSX : CVQ

Afexa Life Sciences Inc.

September 15, 2008 08:10 ET

News Conference Notice: Results of Four City Study on COLD-FX Involving 780 Participants to Be Discussed by Principal Investigator, Dr. Gerald Predy and Company Officials

EDMONTON, ALBERTA--(Marketwire - Sept. 15, 2008) - CV Technologies Inc. (TSX:CVQ) -



WHAT: News Conference to discuss results of COLD-FX's biggest trial to
date.

WHO:
- Dr. Gerry Predy, Principal Trial Investigator, Medical Office of
Health, Alberta Health Services and Director of the Northern Alberta
Vaccine Trials and Evaluation Centre.
- Dr. Jacqueline Shan, President, CEO and Chief Scientific Officer, CV
Technologies
- Dr. Sharla Sutherland, Vice President, Clinical and Regulatory
Affairs, CV Technologies

WHERE: # 1800 College Plaza, Northern Alberta Clinical Trials and Research
Centre, 8215 - 112th Street, Edmonton, Alberta

WHEN: 12 noon, MT, Monday, Sept 15, 2008


Note: COLD-FX Beta "B" roll available for TV reporters


Contact Information

  • CV Technologies Inc., Edmonton Research Park
    Warren Michaels
    Vice President, Communications
    (780) 432-0022